Canadian cannabis stocks, including Tilray (TLRY), surged following reports that President Donald Trump could sign an executive order as soon as Monday reclassifying marijuana from a Schedule I drug like heroin to the less-restrictive Schedule III category, alongside steroids and codeine. The potential reclassification would allow cannabis companies to deduct business expenses under IRS rules, improve access to banking services, and enable expanded medical research. More News from Barchart Valued at a ...

Canopy Growth Corporation ( CGC ) is the Canadian cannabis umbrella operation that grows and sells a range of cannabis, hemp, and cannabinoid-based products, largely by way of brands such as Tweed, DOJA, and 7 Acres. In addition, it ownsI focus on producing objective, data-driven research, mostly about small- to mid-cap companies, as these tend to be overlooked by many investors. From time to time, though, I also look at large-cap names, just to give a fuller sense of the broader equity markets.Analyst’s Di ...

Cannabis stocks surged on Friday amid reports that President Donald Trump will soon ease federal marijuana restrictions through executive action, with shares jumping as much as 54% across the sector. While major players Tilray Brands (TLRY) and Canopy Growth (CGC) captured headlines with their double-digit rallies, one company has quietly dominated the 2025 performance charts. More News from Barchart Curaleaf Holdings (CURLF) shares are up 124% year-to-date (YTD), outpacing every other cannabis stock ...

Mr. Mavroudis is a professional portfolio manager specializing in institutional and private portfolios. He focuses on risk management, which is accompanied by in-depth financial market analysis (fundamental, macro and technical) to control the risk undertaken by the portfolios. He invests in all financial instruments globally (stocks, bonds, fx, commodities), restructuring investment portfolios based on prevailing conditions and the needs of each client-investor. Mr. Mavroudis has successfully navigated all ...

Green Thumb Industries rallied last week on renewed hope of cannabis rescheduling from the Trump administration. The news appeared in a Washington Post article released on Thursday. US MSOs and Canadian cannabis LPs saw largeWelcome to the home of The Cannabis Report. I cover the cannabis sector and other sectors. I am most interested in technical stock analysis, option strategies, small cap strategies, and emerging markets. Feel free to contact me with any questions about publicly traded stocks in the cann ...

Core Insights - Green Thumb Industries experienced a rally due to renewed optimism regarding cannabis rescheduling from the Trump administration, as reported in a Washington Post article [1] Industry Summary - The news has positively impacted US multi-state operators (MSOs) and Canadian cannabis licensed producers (LPs), indicating a potential shift in the regulatory landscape for the cannabis sector [1]

Core Insights - Cannabis stocks experienced a significant surge on December 12, 2025, due to reports of President Trump's plans to ease federal marijuana regulations by reclassifying it to Schedule III from Schedule I, leading to increased investor optimism [1][2] - The potential reclassification could allow cannabis companies to benefit from different tax regulations and encourage further investment, with expectations for the change to materialize early next year [2][4] - The reported policy change is viewed positively by industry experts, as it would facilitate banks in providing services to cannabis-related businesses, with a finalized rule anticipated by summer 2026 [4] Market Performance - Major cannabis ETFs saw substantial gains on December 12, 2025, including Amplify Seymour Cannabis ETF (CNBS) up over 54%, Roundhill Cannabis ETF (WEED) up 55.7%, Advisorshares Pure US Cannabis ETF (MSOS) up 54.3%, Amplify Alternative Harvest ETF (MJ) up 42.8%, Advisorshares Pure Cannabis ETF (YOLO) up 34.5%, and Cambria Cannabis ETF (TOKE) up 20.9% [1][3] - Despite the recent surge, cannabis stocks have faced challenges since the pre-Covid boom, with Tilray (TLRY) shares down approximately 84.4% over the past five years and the MJ ETF declining about 78.9% during the same period [5][6] Industry Outlook - The potential regulatory shift is seen as a step towards normalizing cannabis under federal law, with increasing acceptance and easing regulations in several states [5] - The cannabis industry has shown signs of recovery during Trump's second term, evidenced by a 37% increase in the MJ ETF and a 53.9% surge in the MSOS ETF [6]

Aurora Cannabis Inc. (NASDAQ:ACB) ranks among the best sin stocks to buy in 2026. Aurora Cannabis Inc. (NASDAQ:ACB) has recently been making significant market growth in Europe and Australia, with the company stating on December 2 that its subsidiary, MedReleaf Australia, has signed a distribution agreement with Leafio, Montu Australia’s wholesale arm. The partnership intends to give medical professionals training materials while expanding patient access to medical cannabis products throughout Australia. ...

Core Insights - 420 Investor was launched in 2013, coinciding with Colorado's legalization of cannabis for adult use, and has now transitioned to Seeking Alpha for broader coverage of the cannabis sector [1] - The service provides extensive resources for investors, including model portfolios, videos, and written materials focused on cannabis stocks [1] - Alan Brochstein, a pioneer in cannabis investment analysis, has been managing the 420 Investor group and closely follows 20 cannabis stocks, offering investment news and earnings report analyses [1] Company and Industry Overview - The cannabis industry has seen significant interest from investors, particularly with the establishment of platforms like 420 Investor that cater specifically to this market [1] - The transition of 420 Investor to Seeking Alpha indicates a strategic move to enhance visibility and accessibility for investors interested in cannabis stocks [1] - Alan Brochstein's background in financial services and his role in founding New Cannabis Ventures highlight the growing importance of specialized financial analysis in the cannabis sector [1]

Core Insights - The cannabis industry is poised for increased profitability as shares of Tilray Brands surged 65% in a week, driven by investor optimism regarding potential regulatory changes from the Trump administration [1][5]. Regulatory Changes - President Trump is reportedly considering reclassifying marijuana from a Schedule I drug to a Schedule III drug, with a decision expected as soon as December 15 [3]. - Schedule I drugs are defined as having no accepted medical use and a high potential for abuse, while Schedule III drugs have moderate to low potential for dependence [4]. Financial Implications - A reclassification could facilitate cannabis companies' access to banking and traditional financial services, and allow them to claim federal tax deductions for business expenses currently disallowed [6]. - This regulatory shift is likely to enhance after-tax profits for Tilray and other cannabis producers, potentially leading to a more lucrative market environment [6].